Human growth hormone (hGH) is a $3.5 billion industry, but it's plagued by a major issue: All of the current versions of hGH (somatropin) – Novo Nordisk's Norditropin, Eli Lilly and Co.'s Humatrope, Roche AG unit Genentech Inc.'s Nutropin-AQ, Merck Serono's Saizen, Teva Pharmaceutical Industries Ltd.'s Tev-tropin, LG Life Science Ltd.'s Valtropin and Omnitrope, sold by Novartis AG's generic group Sandoz – have to be injected daily.
IMS Institute for Healthcare Informatics is out with its latest prediction for sales of medicines through 2018, when global spending is expected to reach between $1.28 trillion and $1.31 trillion, an increase of $290 million to $320 million over 2013 levels.
IMS Institute for Healthcare Informatics is out with its latest prediction for sales of medicines through 2018, when global spending is expected to reach between $1.28 trillion and $1.31 trillion, an increase of $290 million to $320 million over 2013 levels.
After brokering the sale of Cambridge, Mass.-based Idenix Pharmaceuticals Inc. to Merck & Co. Inc., of Whitehouse Station, N.J., earlier this year, the biotech's former president and CEO, Ronald Renaud, is taking on a new project as CEO of Rana Therapeutics Inc., helping the biotech develop its long noncoding RNA (lncRNA) technology.
We've known that Intercept Pharmaceuticals Inc.'s FLINT trial evaluating obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) was positive since the data safety monitoring stopped the trial early for positive efficacy in January. (See BioWorld Today, Jan. 10, 2014.)
According to calculations by Morrison & Foerster LLP's Biometer, the average up-front payment for biotech deals in the third quarter came in at $43.7 million, up from $30.4 million in the year-ago quarter.
A report from Tufts Center for the Study of Drug Development (CSDD) highlights the evolving relationships between contract research organizations (CROs) and clinical trial sponsors through the adoption of strategic partnerships.
LA JOLLA, Calif. – Gene therapy has come a long way from using retroviral vectors to insert gamma-chain transgenes into cells of children with severe combined immunodeficiency in the early 1990s, an act that increased the risk of developing leukemia.
